ask our doctors

Thrombotic Thrombocytopenic Purpura

Get the facts on Thrombotic Thrombocytopenic Purpura treatment, diagnosis, staging, causes, types, symptoms. Information and current news about clinical trials and trial-related data, Thrombotic Thrombocytopenic Purpura prevention, screening, research, statistics and other Thrombotic Thrombocytopenic Purpura related topics. We answer all your qestions about Thrombotic Thrombocytopenic Purpura.

Question: Thrombotic thrombocytopenic purpura? With this condition, is a exchange transfusion the only option. Oh and I don't suffer with this. I'm doing research in to blood diseases.

Answer: Since the early 1990s, plasmapheresis has become the treatment of choice for TTP.[12] This is an exchange transfusion involving removal of the patient's blood plasma through apheresis and replacement with donor plasma (fresh frozen plasma or cryosupernatant); the procedure has to be repeated daily to eliminate the inhibitor and ablate the symptoms. Lactate dehydrogenase levels are generally used to monitor disease activity. Plasmapheresis may need to be continued for 1–8 weeks before patients with idiopathic TTP cease to consume platelets and begin to normalize their hemoglobin. No single laboratory test (platelet count, LDH, ADAMTS13 level, or inhibitory factor) is indicative of recovery; research protocols have used improvement or normalization of LDH as a measure for ending plasmapheresis. Although patients may be critically ill with failure of multiple organ systems during the acute illness, including renal failure, myocardial ischemia, and neurologic symptoms, recovery over several months may be complete in the absence of a frank myocardial infarct, stroke, or CNS hemorrhage.[citation needed] Many TTP patients need additional immunosuppressive therapy, with glucocorticoid steroids (e.g. prednisolone or prednisone), vincristine, cyclophosphamide, splenectomy or a combination of the above. Rituximab, a monoclonal antibody targeting B cells, has been successfully used to treat patients with refractory disease.[citation needed] Children with Upshaw-Schulman syndrome receive plasma every two to three weeks prophylactically; this maintains adequate levels of functioning ADAMTS13. Measuring LDH level, platlets counts and schistocytes under high power fields are used to monitor disease progression or remission. :)

Thrombotic Thrombocytopenic Purpura News